Wells Fargo lowered the firm’s price target on Bio-Rad (BIO) to $290 from $320 and keeps an Equal Weight rating on the shares. The firm notes Q1 missed on organic growth and EBITDA as the Middle East conflict hit demand and margins, while also leading it to materially cut FY26 revenue/margin guidance.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIO: